Ovarian cancer, neoadjuvant chemotherapy, biomarkers, homologous recombination deficiency, TILS
Stage III colon cancer, RAS mutation, BRAFV600E mutation, MSI/dMMR, adjuvant, survival after relapse, time to recurrence